Abstract: We recently showed that interleukin (IL)-6-type cytokine signaling in adipocytes induces free fatty acid release from visceral adipocytes, thereby promoting obesity-induced hepatic insulin resistance and steatosis. In addition, IL-6-type cytokines may increase the release of leptin from adipocytes and by those means induce glucagon-like peptide 1 (GLP-1) secretion. We thus hypothesized that IL-6-type cytokine signaling in adipocytes may regulate insulin secretion. To this end, mice with adipocyte-specific knockout of gp130, the signal transducer protein of IL-6, were fed a high-fat diet for 12 weeks. Compared with control littermates, knockout mice showed impaired glucose tolerance and circulating leptin, GLP-1, and insulin levels were reduced. In line, leptin release from isolated adipocytes was reduced, and intestinal proprotein convertase subtilisin/kexin type 1 (Pcsk1) expression, the gene encoding PC1/3, which controls GLP-1 production, was decreased in knockout mice. Importantly, treatment with the GLP-1 receptor antagonist exendin 9-39 abolished the observed difference in glucose tolerance between control and knockout mice. Ex vivo, supernatant collected from isolated adipocytes of gp130 knockout mice blunted Pcsk1 expression and GLP-1 release from GLUTag cells. In contrast, glucose-and GLP-1-stimulated insulin secretion was not affected in islets of knockout mice. In conclusion, adipocyte-specific IL-6 signaling induces intestinal GLP-1 release to enhance insulin secretion, thereby counteracting insulin resistance in obesity. 
Introduction
High production and release of interleukin-6 (IL-6) from adipose tissue may contribute to dys-regulated metabolism in obesity and, thus, contribute to the development of insulin resistance (1) (2) (3) . Consistently, we recently reported a role of IL-6 signaling in adipocytes in the development of obesity-associated liver insulin resistance and steatosis by making use of adipocyte-specific glycoprotein 130 (gp130) knockout (gp130 Δadipo ) mice (4) . gp130 is a common signal transducer protein of all IL-6-type cytokines which comprises eight different cytokines such as IL-6, interleukin 11 and leukemia inhibitor factor (LIF) (5) . It was previously suggested that these IL-6-type cytokines may impact on leptin production in adipose tissue (6) (7) (8) , thereby potentially mediating a protective effect on glucose metabolism. Interestingly, leptin was found to stimulate the release of glucagon-like peptide-1 (GLP-1) from enteroendocrine cells (9) . GLP-1 is an important inducer of glucose-stimulated insulin release in vivo and it also inhibits gastric emptying and glucagon secretion (10) . Hence, identification of factors promoting endogenous GLP-1 release is of interest since enhancing endogenous GLP-1 secretion may be a useful strategy to prevent pancreatic β-cell failure in insulin-resistant obese patients and subsequent development of type 2 diabetes (11) . Active GLP-1 is mainly secreted into circulation from intestinal L cells after being cleaved from its precursor proglucagon by the prohormone convertase 1/3 (PC1/3) (10; 12; 13). The latter is encoded by proprotein convertase subtilisin/kexin type 1 (Pcsk1) that is expressed in intestinal L cells as well as alpha cells of pacreatic islets (13) . Accordingly, GLP-1 can also be produced in pancreatic islets where it shows paracrine actions (12) .
In fact, it has recently been proposed that GLP-1 originating from pancreatic islets may 5 be more important for glucose homeostasis than GLP-1 produced in intestinal L cells (14; 15) .
In the present study, we hypothesized that adipocyte-specific IL-6-type cytokine signaling induces leptin-mediated GLP-1 release in obese mice thereby improving glucose-stimulated insulin release and glucose tolerance.
Research Design and Methods

Animals
Adipocyte-specific gp130 knockout mice (gp130 adipo ) on a C57BL/6J background were generated by crossing gp130 floxed (gp130 F/F ) mice (16) with animals expressing the Cre recombinase controlled by the Adipoq promoter (AdipoqCre mice; purchased from The Jackson Laboratory, Bar Harbor, ME, USA). Six weeks-old male mice were fed ad libitum with standard rodent diet (chow) or high fat diet (HFD; D12331, Research Diets, New Brunswick, USA) for 12 weeks. HFD consisted of 58% of calories derived from fat, 28% from carbohydrate and 16% from protein. All protocols conformed to the Swiss animal protection laws and were approved by the Cantonal Veterinary Office in Zurich, Switzerland.
Intraperitoneal glucose and insulin tolerance test
Intraperitoneal glucose and insulin tolerance tests were performed as described (17) . To block GLP-1 action, exendin 9-39 (25 nM/kg body weight; Bachem, Bubendorf, Switzerland), was injected intraperitoneally 1 minute prior to glucose injection. Blood 6 glucose concentration was measured in blood from tail-tip bleedings using a glucometer (AccuCheck Aviva, Roche Diagnostics, Rotkreuz, Switzerland).
Oral glucose tolerance test
Glucose (2g/kg body weight) was orally administered in overnight fasted mice. To block GLP-1 action, exendin 9-39 (25 nM/kg body weight), was injected intraperitoneally 15 minutes prior to oral glucose administration. Blood glucose concentration was measured in blood from tail-tip bleedings using a glucometer (AccuCheck Aviva).
Food intake
Food intake was determined using a metabolic and behavioral monitoring system (PhenoMaster, TSE Systems, Bad Homburg, Germany) as described (18) .
Leptin release from isolated adipocytes
Adipocytes were isolated as described (19) . Isolated adipocytes were incubated in the absence or presence of 1 nM/l CNTF (BioLegend, San Diego, CA, USA), 1 nM/l CT-1 (BioLegend), 5 nM/l recombinant IL-6 (AdipoGen), 10 nM/l IL-11 (Lucerna Chem, Luzern, Switzerland), 2.5 nM/l LIF (Miltenyi Biotec, Bergisch Gladbach, Germany) or 1 nM/l OSM (BioLegend) for four hours. Leptin levels were measured using MSD technology (Meso Scale Discovery, Gaithersburg, MD, USA).
Blood sampling
To prevent GLP-1 degradation, sitagliptine (25µg/g body weight; Sigma, Buchs, Switzerland) was injected intraperitoneally 30 minutes before oral or intraperitoneal 7 glucose administration. Of note, sitagliptine was demonstrated to increase circulating GLP-1 levels in mice (20) . EDTA (5mM) and Diprotin A (0.1 mM; Sigma) were added to the collected blood followed by immediate centrifugation at 4°C and plasma was stored at -80°C until further processing.
Determination of plasma parameters
Plasma active GLP-1 and leptin were determined using MSD technology. Plasma insulin levels were measured using an ELISA kit as described previously (21) . ELISA kits were used to measure plasma adiponectin (AdipoGen, Liestal, Switzerland), DPP IV (Abnova, Taipei City, Taiwan) and IL-6 (BioLegend, San Diego, CA, USA).
RNA extraction and quantitative reverse transcription-PCR (RT-PCR)
Total RNA was extracted (NucleoSpin, Macherey-Nagel, Düren, Germany) and concentration was determined spectrophotometrically (Nanodrop 1000; Nanodrop Technologies, Boston, MA). RNA was reverse transcribed with GoScript Reverse Transcription System (Promega, Madison, WI, USA). Taqman assays (Applied Biosystems, Rotkreuz, Switzerland) were used for real-time PCR amplification. The following PCR primers (Applied Biosystems) were used: leptin: Mm00434759 m1; pcsk1:
Mm00479023_m1. Relative gene expression was obtained after normalization to 18sRNA (Applied Biosystems), using the formula 2 -ΔΔcp (22) .
Experiments in isolated islets
For mouse islet isolation, pancreata were perfused via the pancreatic duct with a collagenase solution (Worthington, Lakewood, NJ), excised and digested in the same 8 solution at 37 o C for 27 minutes. The digest was sequentially filtered through 500 μm and 70 μm cell strainers (BD Falcon). Islets were handpicked under a microscope and cultured in 24-well ECM coated plates (Novamed Ltd., Jerusalem, Israel) for 40 hours in RPMI-1640 containing 11.1 mM glucose, 100 units/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamax, 50 μg/ml gentamycin, 10 μg/ml Fungison and 10 % FCS at a density of 25 islets/well. To determine glucose stimulated insulin secretion islets were preincubated for 30 minutes in modified Krebs-Ringer bicarbonate buffer (KRB) containing 115 mM NaCl, 4.7 mM KCl, 2.6 mM CaCl2 2H2O, 1.2 mM KH2PO4, 1.2 mM MgSO4 7H2O, 10 mM HEPES, 0.5 % bovine serum albumin, pH 7.4 and 2.8 mM glucose. KRB was then replaced by KRB 2.8 mM glucose and collected after 1 hour (basal insulin release), followed by collection of 1 hour release in KRB 16.7 mM glucose (stimulated insulin release) or KRB 16.7 mM glucose with 100 nM GLP-1(7-36) amide (Bachem, Switzerland). For determination of the insulin content islet cells were extracted with 0.18 N HCl in 70 % EtOH. Insulin concentrations were determined using mouse insulin ultrasensitive mouse/rat insulin kit (Mesoscale Discovery, Rockville, MD).
Ileum explants
Terminal ileum was dissected, flushed in PBS and cut into smaller pieces of 0.5 cm length. Explants were maintained in culture medium (Krebs buffer containing 0.1% BSA, 5 mM D-Glucose and 100 µM of Diprotin A (Sigma)). After 1 hour, medium was changed and supplemented with 15 mM D-Glucose or 0.1 µM recombinant leptin (BioTechne Ltd, Abingdon, U.K.) for 2 hours. Thereafter, supernatants were collected and explants were snap frozen until further processing. 
Data analysis
Data are presented as means ± SEM. Data were analyzed by unpaired two-tailed Student's t test, one sample t test, one-way ANOVA with Newman-Keuls correction for multiple group comparisons or two-way ANOVA with Bonferroni multiple comparisons.
All statistical tests were calculated using the GraphPad Prism 5.04 (GraphPad Software, San Diego, CA, USA). P values < 0.05 were considered to be statistically significant.
Results
Impaired glucose tolerance in HFD-fed gp130 Δadipo mice
To investigate a possible role of adipocyte-specific IL-6-type cytokine signaling in glucose metabolism, intraperitoneal glucose tolerance tests were performed in adipocyte-specific gp130 knockout mice (gp130 Δadipo ) and control littermate mice (gp130 F/F ) fed a chow or high fat diet (HFD) for twelve weeks. As previously shown, gp130 protein levels are reduced in isolated adipocytes but not in skeletal muscle and liver of gp130 Δadipo mice compared to control littermates, and body weight (4) as well as food intake was similar in both genotypes (Supplemental Fig. 1 ). As depicted in Fig. 1A and B, depletion of gp130 in adipocytes led to a stronger deterioration of intraperitoneal glucose tolerance in HFD-fed mice. In contrast, intraperitoneal insulin tolerance was improved in HFD-fed gp130 Δadipo mice ( Fig. 1C and D) , confirming previous findings obtained from hyperinsulinemic-euglycemic clamp studies (4) . Such data indicate that impaired glucose tolerance in knockout mice may be the result of blunted glucosestimulated insulin secretion. Indeed, glucose-stimulated circulating insulin levels were significantly lower after intraperitoneal glucose injection in HFD-fed gp130 Δadipo compared to gp130 F/F mice (Fig. 1E ). To investigate whether impaired β-cell function may drive the observed phenotype, glucose-stimulated insulin secretion (GSIS) was assessed in islets ex vivo. Of note, GSIS was not impaired in islets isolated from HFDfed gp130 Δadipo mice when compared to control littermates (Fig. 1F) . Moreover, insulin content was higher in HFD-fed knockout compared to control mice (Supplemental Fig.   2 ). Hence, deteriorated glucose-stimulated insulin levels in vivo do not result from defective β-cell function. Rather, impaired incretin secretion may constitute the observed metabolic phenotype.
Reduced circulating GLP-1 levels in obese gp130 Δadipo mice
To assess a potential involvement of impaired incretin secretion, oral glucose tolerance tests were performed. As depicted in Fig. 2A and B, oral glucose tolerance was significantly impaired in HFD-fed knockout mice, paralleled by a ~40% reduction in circulating insulin levels (Fig. 2C ). Of note, the difference between knockout and control mice was even more pronounced after oral compared to intraperitoneal glucose administration [~20% difference in area under the curve (AUC) between HFD-fed gp130 Δadipo and control littermates after oral administration (Fig. 2B ) vs. ~10% difference in AUC after intraperitoneal glucose injection (Fig. 1B) ]. Since glucose clearance during oral glucose tolerance test is augmented by incretins (23) , such data further support a role for decreased incretin secretion as a cause for impaired glucose tolerance in gp130 knockout mice. Indeed, basal as well as glucose-stimulated levels of glucagon-like peptide-1 (GLP-1) were reduced by ~50% in knockout mice (Fig. 2D) . Importantly, the GLP-1 receptor antagonist exendin 9-39 (24) blunted the difference in glucose tolerance between HFD-fed control and knockout mice (Figs. 2E and F). In fact, exendin 9-39 significantly blunted AUC in gp130 F/F mice (1272±57 mmol/l*min in control vs. 1500±51 mmol/l*min in exendin 9-39 treated mice; p<0.05) but not in gp130 Δadipo mice (1507±34 mmol/l*min in control vs. 1567±34 mmol/l*min in exendin 9-39 treated mice; p=0.23).
Besides affecting oral glucose tolerance, exendin 9-39 treatment abrogated impaired intraperitoneal glucose tolerance in gp130 Δadipo mice (Fig. 2G) , suggesting that reduced basal GLP-1 levels (Fig. 2D) contributed to impaired intraperitoneal glucose tolerance in untreated mice (Fig. 1A and B 
IL-6 signaling in adipocytes contributes to obesity-induced circulating leptin levels
Reduced circulating GLP-1 levels in HFD-fed gp130 Δadipo mice may result from enhanced degradation by dipeptidyl peptidase IV (DPP IV) that is increasingly released from adipose tissue in obesity (10; 25). However, plasma DPP IV levels were similar in HFD-fed gp130 F/F and gp130 Δadipo mice (Supplemental Fig. 3 ), indicating that IL-6-type cytokine signaling did not affect circulating DPP IV levels and, hence, was not responsible for blunted GLP-1 levels in knockout mice. Circulating GLP-1 derives almost completely from enteroendocrine L cells (12) . Thus, reduced circulating GLP-1 levels in gp130 knockout mice may result from blunted intestinal secretion. Indeed, glucosestimulated GLP-1 secretion from intestinal explants harvested from HFD-fed gp130 Δadipo mice was reduced (Fig. 3A) , whereas its release from islets isolated from HFD-fed knockout mice remained unaffected (Supplemental Fig. 4) . Hence, reduced circulating GLP-1 levels in HFD-fed gp130 Δadipo mice resulted from its blunted release from enteroendocrine cells.
Recently, different adipose-derived circulating factors were shown to affect GLP-1 release from intestinal cells. In fact, circulating IL-6 was shown to stimulate GLP-1 secretion thereby enhancing glucose-stimulated insulin secretion (26) . Moreover, the two adipokines adiponectin and leptin were reported to induce GLP-1 secretion from intestinal L cells (9; 27). As depicted in Supplemental Fig. 5 , circulating IL-6 and adiponectin levels were similar between HFD-fed gp130 F/F and gp130 Δadipo mice. In contrast, plasma leptin levels were reduced by ~40% in gp130 Δadipo mice (Fig. 3B) despite similar body weight (4), potentially contributing to their reduced GLP-1 levels. To analyze the impact of IL-6-cytokine signaling on leptin production in adipocytes, its expression and release were analyzed in isolated adipocytes of chow-and HFD-fed 13 knockout and control mice. As expected, HFD induced leptin mRNA expression in and release from adipocytes of control mice (Fig. 3C and D) . Importantly, leptin release from adipocytes was significantly blunted in HFD-fed knockout mice (Fig. 3D) , whereas its expression was unchanged (Fig. 3C) . In addition, leptin content in isolated adipocytes of HFD-fed mice was similar between the genotypes (Fig. 3E) . Hence, IL-6-type cytokine signaling in adipocytes affects leptin release but not its transcription and protein synthesis. We next wanted to investigate which member of the IL-6-type cytokine family mediated the effect on leptin release. To this end, isolated adipocytes of chow-fed gp130 F/F and gp130 Δadipo mice were incubated with the IL-6-type cytokine family members ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), IL-6, IL-11, LIF or oncostatin M (OSM), which were previously suggested to affect leptin production or were suggested as potential targets to treat obesity (5-8; 28) . While CNTF, CT-1, IL-11, LIF and OSM had no significant effect on leptin release, IL-6 stimulated leptin secretion in isolated adipocytes gp130-dependently (Fig. 3F) . Taken together, IL-6 induced leptin release from adipocytes thereby contributing to elevated circulating leptin levels in HFDfed mice.
Leptin induces Pcsk1 expression and GLP-1 release in enteroendocrine cells
Leptin induces GLP-1 release from the enteroendocrine cell line GLUTag cells (9; 29) . Such release of GLP-1 is regulated by PC1/3 in intestinal cells (10; 13). Indeed, expression of proprotein convertase subtilisin/kexin type 1 (Pcsk1), the gene encoding PC1/3 (13), was significantly increased by leptin treatment (Fig. 4A) . Importantly, leptin also stimulated Pcsk1 expression in L cell-rich ileum (14) explants harvested from HFDfed gp130 F/F mice (Fig. 4B) . Next, experiments in GLUTag cells that were incubated with 14 supernatant harvested from isolated adipocytes were performed to further explore the proposed adipo-enteroendocrine axis driven by leptin. As shown in Fig. 4C , GLP-1 release was significantly blunted in GLUTag cells incubated with supernatants collected from adipocytes of HFD-fed gp130 Δadipo mice. Of note, leptin concentration was reduced in such supernantants as shown above (Fig. 3D) . Importantly, leptin neutralization reversed observed difference on GLP-1 release in GLUTag cells incubated with supernatant collected from adipocytes (Fig. 4D) suggesting a critical role of leptin in the observed effect. In parallel, Pcsk1 expression was reduced (Fig. 4E ) in GLUTag cells incubated with supernatants collected from adipocytes of HFD-fed gp130 Δadipo mice, an effect that was reversed upon leptin neutralization (Fig. 4F) . Likewise, expression of Pcsk1 was reduced in the ileum of HFD-fed knockout mice (Fig. 4G) . Collectively, our data suggest that IL-6-type cytokine signaling in adipocytes promotes intestinal GLP-1 release leptin-dependently, probably by stimulating Pcsk1 expression.
Discussion
The present study suggests that adipocyte-specific IL-6-type cytokine signaling promotes leptin-mediated GLP-1 release from enteroendocrine cells in obesity thereby improving glucose-stimulated insulin release and glucose tolerance ( Lack of IL-6-type cytokine signaling in adipocytes blunts circulating leptin levels independently of fat pad mass (4). Interestingly, reduced circulating leptin levels in knockout mice were paralleled by reduced leptin release from but similar mRNA expression in adipocytes indicating that gp130 depletion affects leptin secretion but not leptin transcription. Accordingly, it has been suggested that circulating signals regulate leptin on a post-transcriptional level, whereas the long-term nutritional status affects leptin mRNA expression (31) . In the past, several IL-6-type cytokines were suggested to affect leptin production or were proposed as potential targets to treat obesity (5-8; 28) .
Here, we suggest that IL-6 contributes to obesity-induced leptin release from adipocytes, adding another metabolic function to the pleiotropic actions of IL-6 (32-34). In fact, among all tested IL-6-type cytokines only IL-6 significantly increased leptin release from isolated adipocytes. Consistently, treatment of HFD-fed C57BL/6 mice with an anti-IL-6 receptor antibody reduced circulating leptin levels (35) . Clearly, we cannot rule out that other IL-6-type family members and/or other molecules binding gp130 such as superantigens (36) contribute to reduced circulating leptin levels in knockout mice. In addition, compensatory changes in the production of other adipose-derived factors in knockout mice may have contributed to reduced leptin levels.
Despite impaired glucose tolerance, insulin sensitivity was improved in HFD-fed gp130 Δadipo mice. This observation may be explained by reduced portal FFA flux in knockout mice leading to blunted hepatic insulin resistance and steatosis (4). Hence, IL-6-cytokine signaling in adipocytes may promote both protective as well as harmful effects on glucose metabolism (Fig. 5) . Physiologically, increased IL-6-mediated release of FFA and leptin from adipocytes in obesity may be interpreted as an attempt to reduce lipid stores by increasing lipolysis (FFA release) and by lowering lipid accumulation via leptin-mediated reduction of food intake. Notably, the observed leptin-mediated effect of IL-6 on circulating GLP-1 levels may be additive to the direct effect of IL-6 on GLP-1 release from enteroendocrine cells (26) .
Of note, reduced circulating leptin levels in knockout mice did not significantly affect body weight (4) Supplemental Figure 5 A B
